Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Glucose-dependent insulinotropic polypeptide is a pancreatic polypeptide secretagogue in humans

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hydroxylated Long-Chain Acylcarnitines are Biomarkers of Mitochondrial Myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Glucose-dependent insulinotropic polypeptide(GIP) has been suggested to stimulate the secretion of pancreatic polypeptide(PP), an islet hormone thought to regulate gut motility, appetite and glycemia.

OBJECTIVE: To determine whether human GIP1-42 (hGIP) stimulates PP secretion.

METHOD: As glycemia modulates the secretion of PP, we measured plasma PP concentrations from two studies in healthy men(n=10) and in patients with type 2 diabetes (T2D)(n=12), where hGIP1-42 had been administered intravenously during fasting glycemia, hyperglycemia(12mmol/L) and insulin-induced hypoglycemia (targets: 2.5mmol/L(healthy)/3.5mmol/L(T2D)). Porcine GIP1-42 (pGIP) was also infused intra-arterially in isolated porcine pancreata(n=4).

RESULTS: Mean fasting plasma glucose concentrations were ~5mmol/L(healthy) and ~8mmol/L(T2D).At fasting glycemia, PP concentrations were higher during intravenous hGIP1-42 infusion compared with saline in healthy men (mean(SEM), net iAUCs0;30min 403(116) vs. -6(57) pmol/L×min,p=0.004) and in patients with T2D (905(177) vs. -96(86)pmol/L×min,p=0.009). During hyperglycemic clamping, PP concentrations were significantly higher during hGIP1-42 infusion compared with saline in patients with T2D (771(160) vs. -183(117)pmol/L×min,p=0.001), but not in healthy individuals (-8(86) vs. -57(53)pmol/L×min,p=0.69). When PG levels were declining in response to exogenous insulin, PP concentrations were higher during hGIP1-42 infusion compared with saline in healthy individuals (294(88) vs. -82(53)pmol/L×min,p=0.0025), but not significantly higher in patients with T2D(586(314) vs. -120(53),p=0.070). At target hypoglycemia , PP levels surged in both groups during both hGIP1-42 and saline infusions.In isolated pancreata, pGIP1-42 increased PP output in the pancreatic venous effluent (baseline vs. infusion, 24(5) vs. 79(16)pmol/min x min,p=0.044).

CONCLUSION: GIP1-42 increases plasma PP secretion in healthy individuals, patients with T2D and isolated porcine pancreata. Hyperglycemia blunts the stimulatory effect of hGIP1-42 in healthy individuals, but not in patients with T2D.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
ISSN0021-972X
DOI
StatusE-pub ahead of print - 26 okt. 2019

Bibliografisk note

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 58246605